BioCentury | Aug 4, 2015
Company News

Management tracks

...Diagnostic play T2 Biosystems (NASDAQ:TTOO) named Maurice Castonguay CFO. Castonguay was SVP and CFO of Sonus...
BioCentury | Apr 15, 2013
Company News

Sonus, Abbott deal

...complete the review of SNUS's NDA for EchoGen emulsion ultrasound contrast agent. (SNUS earnings, B14) Sonus Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

Sonus regulatory update

...determined that it will regulate all contrast agents as drugs (see BioCentury Extra, July 30). Sonus Pharmaceuticals Inc....
BioCentury | Oct 20, 2008
Clinical News

Custirsen sodium: Phase III start

...of the company's shares to OncoGenex's original shareholders as part of its merger agreement with Sonus Pharmaceuticals Inc....
BioCentury | Oct 6, 2008
Finance

Restructuring watch

...to 27 $26.0 NA 6/30/08 NA Cuts primarily early stage R&D following the merger with Sonus...
BioCentury | Oct 6, 2008
Company News

Seattle Genetics management update

...as SVP of regulatory affairs, formerly SVP of regulatory affairs/quality assurance and clinical research at Sonus Pharmaceuticals Inc....
BioCentury | Sep 8, 2008
Company News

Eagle Pharmaceuticals Pty., OncoGenex Technologies deal

...is formulated with the vitamin E-based Tocosol drug delivery system through its August merger with Sonus Pharmaceuticals Inc....
BioCentury | Aug 25, 2008
Company News

OncoGenex Technologies, Sonus cancer news

...OncoGenex and Sonus completed their previously announced merger to form OncoGenex Pharmaceuticals Inc. The combined company...
...expected to last until 1Q09 (see BioCentury, June 2). OncoGenex Technologies Inc. , Vancouver, B.C. Sonus Pharmaceuticals Inc....
BioCentury | Aug 11, 2008
Company News

Sonus, Bayer deal

...received an exclusive, worldwide license to preclinical caspase activators from Bayer’s Bayer Healthcare LLC unit. Sonus...
...compounds for cancer. Bayer retains rights to develop the non-core compounds for all other indications. Sonus...
...front and is eligible for undisclosed milestones, plus royalties. Further financial terms were not disclosed. Sonus Pharmaceuticals Inc....
BioCentury | Jul 14, 2008
Company News

Isis, OncoGenex Technologies deal

...for solid tumors (see BioCentury, March 21 & May 2, 2005). OncoGenex is merging with Sonus Pharmaceuticals Inc....
Items per page:
1 - 10 of 264
BioCentury | Aug 4, 2015
Company News

Management tracks

...Diagnostic play T2 Biosystems (NASDAQ:TTOO) named Maurice Castonguay CFO. Castonguay was SVP and CFO of Sonus...
BioCentury | Apr 15, 2013
Company News

Sonus, Abbott deal

...complete the review of SNUS's NDA for EchoGen emulsion ultrasound contrast agent. (SNUS earnings, B14) Sonus Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

Sonus regulatory update

...determined that it will regulate all contrast agents as drugs (see BioCentury Extra, July 30). Sonus Pharmaceuticals Inc....
BioCentury | Oct 20, 2008
Clinical News

Custirsen sodium: Phase III start

...of the company's shares to OncoGenex's original shareholders as part of its merger agreement with Sonus Pharmaceuticals Inc....
BioCentury | Oct 6, 2008
Finance

Restructuring watch

...to 27 $26.0 NA 6/30/08 NA Cuts primarily early stage R&D following the merger with Sonus...
BioCentury | Oct 6, 2008
Company News

Seattle Genetics management update

...as SVP of regulatory affairs, formerly SVP of regulatory affairs/quality assurance and clinical research at Sonus Pharmaceuticals Inc....
BioCentury | Sep 8, 2008
Company News

Eagle Pharmaceuticals Pty., OncoGenex Technologies deal

...is formulated with the vitamin E-based Tocosol drug delivery system through its August merger with Sonus Pharmaceuticals Inc....
BioCentury | Aug 25, 2008
Company News

OncoGenex Technologies, Sonus cancer news

...OncoGenex and Sonus completed their previously announced merger to form OncoGenex Pharmaceuticals Inc. The combined company...
...expected to last until 1Q09 (see BioCentury, June 2). OncoGenex Technologies Inc. , Vancouver, B.C. Sonus Pharmaceuticals Inc....
BioCentury | Aug 11, 2008
Company News

Sonus, Bayer deal

...received an exclusive, worldwide license to preclinical caspase activators from Bayer’s Bayer Healthcare LLC unit. Sonus...
...compounds for cancer. Bayer retains rights to develop the non-core compounds for all other indications. Sonus...
...front and is eligible for undisclosed milestones, plus royalties. Further financial terms were not disclosed. Sonus Pharmaceuticals Inc....
BioCentury | Jul 14, 2008
Company News

Isis, OncoGenex Technologies deal

...for solid tumors (see BioCentury, March 21 & May 2, 2005). OncoGenex is merging with Sonus Pharmaceuticals Inc....
Items per page:
1 - 10 of 264